PFS and OS in patients from M13-982 and MURANO with R/R CLL with del(17p) or TP53 mutation who completed ≥2 years of venetoclax therapy. (A) PFS from treatment initiation in 74 responders from M13-982 who remained on venetoclax for ≥2 years. (B) PFS from randomization in 31 patients from MURANO with del(17p)/TP53 mutation who completed VenR therapy without PD. (C) OS in 74 responders from M13-982 who remained on venetoclax for ≥2 years. (D) OS in 31 patients from MURANO with del(17p)/TP53 mutation who completed VenR therapy without PD. mut, mutated; NA, not applicable.